Results 141 to 150 of about 56,596 (269)

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 614-638, September 2026.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

Feline sporotrichosis: a case series of itraconazole-resistant Sporothrix brasiliensis infection

Brazilian Journal of Microbiology, 2020
Ceres Cristina Tempel Nakasu, S. Waller, M. Ripoll, M. R. A. Ferreira, F. Conceição, Angelita dos Reis Gomes, Luiza da Gama Osório, R. D. de Faria, M. Cleff   +8 more
semanticscholar   +1 more source

Venetoclax for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: Prospects, resistance mechanisms and management strategies

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
Resistance to venetoclax has become a critical bottleneck limiting its long‐term clinical benefits. A thorough understanding of the underlying resistance mechanisms and the development of novel strategies to overcome resistance are central to improving survival outcomes in elderly AML patients. Abstract To date, the treatment of acute myeloid leukaemia
Jinlin Zhang, Jile Liu, Mohan Zhao, Xiaoyu Zhang, Linlin Liu, Mengnan Li, Changze Cao, Rui Zhang, Mingfeng Zhao   +8 more
wiley   +1 more source

Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics and the Pharmacokinetics of Balcinrenone When Dosed with a P‐gp Inhibitor

The Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.
Abstract Balcinrenone (AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist with a distinct mode of action being developed as a fixed‐dose combination with the sodium–glucose cotransporter‐2 inhibitor dapagliflozin for the treatment of heart failure with impaired kidney function, and chronic kidney disease.
Anna L. Eriksson, Deeyen Karsanji, Amy H. Shi, Joanna Parkinson, Maria Heijer, Edward Austin, Bosse Lindmark, Charlotta Vedin‐Nilsson, Judith Hartleib‐Geschwindner, Maria Leonsson‐Zachrisson, Hans Ericsson   +10 more
wiley   +1 more source

Prognosis of Patients Infected With Talaromyces marneffei Across Various Risk Factors

Journal of General and Family Medicine, Volume 27, Issue 5, September 2026.
ABSTRACT Background Talaromyces marneffei (TM) is an opportunistic infectious fungus, and more patients in HIV‐negative populations are infected with TM. Methods We reviewed the adult patients with TM infections (TMIs) between November 1, 2020 and April 30, 2025.
JiaXin Wang, YaoMin Wang, RenDing Wang
wiley   +1 more source

A Practical Alternative to Refine the Estimate of fmCYP3A4 and Evaluate Drug–Drug Interaction Potential for Ziftomenib Using PBPK Modeling to Inform Labeling

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 9, September 2026.
ABSTRACT Accurate physiologically based pharmacokinetic (PBPK) simulation of drug–drug interaction (DDI) potential requires estimation of the relative contribution of the impacted pathway. While fraction metabolized by CYP enzymes is usually estimated using dedicated clinical DDI studies with strong CYP inhibitors, this approach might not be available ...
Ian E. Templeton, Chara Litou, Hannah M. Jones, Julie Mackey Ahsan, Marilyn Tabachri, Mollie Leoni, Amitava Mitra   +6 more
wiley   +1 more source

Model‐Based Tacrolimus Dosing Using the Population Pharmacokinetic Analysis Under the Nirmatrelvir/Ritonavir Therapy

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 9, September 2026.
ABSTRACT Nirmatrelvir/ritonavir is an antiviral agent used against severe acute respiratory syndrome coronavirus 2 infection and inhibits cytochrome P450 3A and P‐glycoprotein. The concomitant use of nirmatrelvir/ritonavir markedly increases tacrolimus blood concentrations. Although temporary discontinuation or dose reduction of tacrolimus at the start
Kotaro Itohara, Yoshiki Katada, Takahiro Hatayama, Toshiaki Igarashi, Jiro Ogura, Tomoki Fukushima, Shingo Yamazaki, Masato Homma, Takashi Niwa, Yoshiaki Kato, Nanae Yamamoto, Hideyuki Terazono, Hideo Shiohira, Tomohiro Terada, Ikuko Yano   +14 more
wiley   +1 more source

Leveraging Healthy Volunteers for Anticancer Drug Clinical Pharmacology Studies: A Review Article Featuring Futibatinib as an Example

Clinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACT Early clinical development of anticancer drugs traditionally focused on exploring candidate treatments in patients. For instance, due to their cytotoxic action, administration of chemotherapies to healthy volunteers (HVs) for evaluation of their pharmacokinetic profiles was not considered feasible nor ethical from a safety and tolerability ...
Aernout D. van Haarst, Sabina Paglialunga, Ziv Machnes, Ikuo Yamamiya, Nanae Hangai, Aram Oganesian   +5 more
wiley   +1 more source

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

New England Journal of Medicine, 2007
O. Cornely, J. Maertens, D. Winston, J. Perfect, A. Ullmann, T. Walsh, D. Helfgott, J. Hołowiecki, D. Stockelberg, Y. Goh, M. Petrini, C. Hardalo, R. Suresh, D. Angulo-Gonzalez   +13 more
semanticscholar   +1 more source

Understanding Postmarketing Requirements and Commitments for CYP3A‐Mediated Drug–Drug Interactions: An Analysis of FDA‐Approved Drugs From 2015 to 2024

Clinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACT Addressing knowledge gaps at drug approval through drug–drug interaction (DDI)‐related postmarketing requirements (PMRs) and commitments (PMCs) is essential for safe and effective use. This analysis reviewed CYP3A‐related PMRs and PMCs, the most evaluated enzyme in postmarketing studies, to characterize their scope.
Jingjing Yu, Ichiko Petrie, Sophie Argon, Katie Owens, Isabelle Ragueneau‐Majlessi   +4 more
wiley   +1 more source